Premium
Chronic CNS actions of adiponectin on appetite, metabolism and blood pressure
Author(s) -
Bassi Mirian,
Do Carmo Jussara M,
Silva Alexandre A,
Hall John E
Publication year - 2010
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.24.1_supplement.780.1
Subject(s) - adiponectin , medicine , endocrinology , appetite , leptin , blood pressure , insulin , sympathetic nervous system , obesity , insulin resistance
Acute studies suggest that adiponectin may reduce sympathetic activity and blood pressure (BP) via its action on the central nervous system (CNS). We tested if chronic intracerebroventricular (ICV) infusion of adiponectin at 2 doses (1 or 7 μg/day) in Sprague‐Dawley rats fed high fat diet (HFD) for 8 weeks, and at the high dose (7 μg/day) in spontaneously hypertensive rats (SHR), a model of hypertension associated with sympathetic overactivity, evoked chronic reductions in BP and heart rate (HR). We also determined if chronic ICV adiponectin infusions alter appetite, whole body oxygen consumption (VO 2 ), and insulin and leptin levels. Neither dose of adiponectin infused ICV for 7 days altered BP or HR in the HFD group (115±2 to 112±2 mmHg and 384±6 to 379±6 bpm at 1 μg/day; 109±3 to 111±3 mmHg and 366±5 and 367±5 bpm at 7 μg/day). The higher dose slightly reduced food intake (14±1 to 11±1 g/day), whereas VO 2 , insulin and leptin levels were not affected by the treatment. In SHRs, ICV adiponectin infusion reduced appetite (22±2 to 12±2 g/day) and insulin levels (~55%), but did not alter BP (162±4 to 164±3 mmHg) or HR (312±5 to 322±8 bpm). These results suggest that adiponectin, acting via its direct actions on the CNS, has a small effect to reduce appetite and insulin levels. However, our results indicate that, at the doses used in this study, adiponectin has no long‐term action to reduce BP or HR, or to alter whole body metabolic rate.